Table 2. Distribution of serum biomarkers and other factors by presence of brain metastases at baseline or development of subsequent brain metastases after baseline.
Number of Patients | Number with Brain Metastasis | |||
---|---|---|---|---|
Biomarker | At Baseline | After Baseline | ||
Overall | 104 | 26 (25%) | 25 (24%) | |
CYFRA 21–1 | ||||
≤ 3.3 ng/ml | 56 (54%) | 12 | 15 | |
>3.3 ng/ml | 48 (46%) | 14 | 10 | |
NSE | ||||
≤13 ng/ml | 86 (83%) | 23 | 19 | |
>13 ng/ml | 18 (17%) | 3 | 6 | |
ProGRP | ||||
≤50 pg/ml | 38 (37%) | 12 | 8 | |
>50 pg/ml | 9 (9%) | 1 | 2 | |
Unknown | 57 (55%) | 13 | 15 | |
SCCL-Ag | ||||
≤2.0 ng/ml | 96 (92%) | 25 | 25 | |
>2.0 ng/ml | 8 (8%) | 1 | 0 | |
HE4 | ||||
≤65 pmol/L | 28 (27%) | 8 | 3 | |
>65 pmol/L | 76 (73%) | 18 | 22 | |
TIMP1 | ||||
>55.5 μg/L | 79 (76%) | 21 | 16 | |
Unknown | 25 (24%) | 5 | 9 |